Jérôme Lemonnier

7PUBLICATIONS
65CO-AUTHORS
Molecular targetsEnvironmental epidemiologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 23, 2025
Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial.

Séverine Guiu, Judith Balmaña, Pablo Lemercier

|Aug 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial.

Enora Laas, Anne-Sophie Hamy, Thomas Bachelot

|Aug 22, 2025
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.

François-Clément Bidard, Grégoire Gessain, Thomas Bachelot

|Jul 02, 2025
Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slides.

I Garberis, V Gaury, C Saillard

|Jan 16, 2023
Baseline quality of life and chemotherapy toxicities in patients with early breast cancer.

Idlir Licaj, Elodie Coquan, Tienhan Sandrine Dabakuyo-Yonli

|May 23, 2022
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

Thomas Bachelot, Paul Cottu, Sylvie Chabaud

Pageof 2

Frequent Collaborators

3 joint publications

Frederique Penault-Llorca

3 joint publications

Fabrice Andre

3 joint publications

Thomas Bachelot

3 joint publications

Suzette Delaloge